

- syndrome. *Am J Kidney Dis*. 1986;8(5):345-50
- 13) Korbet SM, editor Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. *Semin Nephrol*; 2003: Elsevier
 - 14) Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. *J Am Soc Nephrol*. 2005;16(4):1061-8
 - 15) Korbet SM. Primary focal segmental glomerulosclerosis. *J Am Soc Nephrol*. 1998;9(7):1333-40
 - 16) Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. *Kidney Int*. 1999;56(6):2236-42
 - 17) D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. *Clin J Am Soc Nephrol*. 2013;8(3):399-406
 - 18) Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. *J Am Soc Nephrol*. 2004;15(8):2169-77
 - 19) Stirling C, Mathieson P, Boulton-Jones J, Feehally J, Jayne D, Murray H, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. *QJM*. 2005;98(6):443-9
 - 20) Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association*. 1999;14(suppl_3):68-73
 - 21) Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. *Nephrology Dialysis Transplantation*. 2000;15(9):1348-56
 - 22) Joardar S, Chatterjee R, Das S, Mani S. Focal Segmental Glomerulosclerosis as the Leading Cause of Idiopathic Nephrotic Syndrome: A different spectrum revealed by mandatory renal biopsy in all patients. *Sri Lanka Journal of Child Health*. 2016;45(2)
 - 23) Park CY, Kim DM, Cho YS, Yoon SH, Chung JH, Chung CH, et al. A case of focal segmental glomerulosclerosis associated with aplastic anemia. *J Korean Med Sci*. 2004;19(6):898-900
 - 24) Kuriyam S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. *Nephron*. 1997;77(2):176-85
 - 25) Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. *Kidney Int*. 2004;66(2):753-60
 - 26) Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. *Osteopath Med Prim Care*. 2007;1(1):14
 - 27) Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. *J Am Soc Nephrol*. 2003;14(suppl 2):S173-S7
 - 28) Yuruk K, Bartels SA, Milstein DM, Bezemer R, Biemond BJ, Ince C. Red blood cell transfusions and tissue oxygenation in anemic hematology outpatients. *Transfusion (Paris)*. 2012;52(3):641-6
 - 29) Vincent J-L, Sakr Y, Lelubre C. The future of observational research and randomized controlled trials in red blood cell transfusion medicine. *Shock*. 2014;41:98-101
 - 30) Canny SP, Orozco SL, Thulin NK, Hamerman JA. Immune Mechanisms in Inflammatory Anemia. *Annu Rev Immunol*. 2023;41:405-29
 - 31) Wacka E, Nicikowski J, Jarmuzek P, Zembron-Lacny A. Anemia and Its Connections to Inflammation in Older Adults: A Review. *J Clin Med*. 2024;13(7)
 - 32) Cases A, Cigarrán S, Luis Górriz J, Nuñez J. Effect of SGLT2 inhibitors on anemia and their possible clinical implications. *Nefrología (English Edition)*. 2024;44(2):165-72
 - 33) Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *J Am Soc Nephrol*. 2006;17(1):17-25
 - 34) Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. *Diverse Effects of Hypoxia on Tumor Progression: Springer*; 2010. p. 105-20
 - 35) Xiong A, Liu Y. Targeting hypoxia inducible factors-1 α as a novel therapy in fibrosis. *Front Pharmacol*. 2017;8:326